These studies demonstrate that human NKp30 CAR TCRKO T cells elicit potent antitumor immunity, extending previous findings on NKp30-based or anti-B7H6 scFv CAR-redirected murine T cells [26,27], and highlight the therapeutic potential of engineered allogeneic NKp30 CAR T cells for CAR T therapy to B7H6-expressing cancers, including not only solid tumors such as melanoma, but importantly to AML as well. This evidence concerns the gene NCR3LG1 and melanoma.